Zepbound vs Ozempic
Two Different Drugs for Two Different Conditions
Zepbound vs Ozempic is one of the most searched medication comparisons online, yet the two drugs are approved for different conditions. Zepbound (tirzepatide) received FDA approval in November 2023 for chronic weight management. Ozempic (semaglutide) has been FDA-approved for type 2 diabetes since 2017. Understanding this indication mismatch is the foundation of every comparison between them.
Quick Answer: The Core Difference
Zepbound
Tirzepatide
Weight management | GLP-1 + GIP
20.9% weight loss (SURMOUNT-1, 15 mg)
Ozempic
Semaglutide
Type 2 diabetes | GLP-1 only
~5-7% weight loss at T2D doses
Because Ozempic is approved for diabetes and Zepbound for obesity, readers comparing both for weight loss should also see the Wegovy vs Zepbound comparison (semaglutide's weight-loss brand vs tirzepatide's weight-loss brand).
Key Takeaways
- Zepbound vs Ozempic is a cross-indication comparison: Zepbound (tirzepatide) is FDA-approved for obesity; Ozempic (semaglutide) is FDA-approved for type 2 diabetes
- Tirzepatide is a dual-agonist (GLP-1 and GIP); semaglutide is a single-agonist (GLP-1 only). That mechanism difference drives tirzepatide's greater average weight loss in trials.
- The 14.9% weight-loss figure cited for semaglutide comes from Wegovy at 2.4 mg (STEP 1), not Ozempic. Ozempic's diabetes doses produce approximately 5-7% weight loss.
- Ozempic holds the stronger cardiovascular outcomes evidence (SELECT 2023: 20% MACE reduction). Zepbound's cardiovascular trial is ongoing as of 2026.
- Use the Zepbound calculator or Ozempic calculator to model your dosing schedule
20.9%
Zepbound Weight Loss (SURMOUNT-1, 15 mg)
20%
Ozempic MACE Reduction (SELECT 2023)
~5 days
Tirzepatide Half-Life
~7 days
Semaglutide Half-Life
Zepbound vs Ozempic: The Essential Difference You Need to Know
Both Zepbound and Ozempic are once-weekly subcutaneous injections. Both belong to the GLP-1 drug class. Both slow gastric emptying, reduce appetite, and affect insulin secretion. The similarity ends at the prescription pad. Zepbound (tirzepatide) is the weight-loss brand of tirzepatide, approved for adults with obesity (BMI 30 or higher) or overweight with at least one weight-related condition. Ozempic (semaglutide) is the diabetes brand of semaglutide, approved for adults with type 2 diabetes to improve blood sugar control.
Most people searching "Zepbound vs Ozempic" are doing so because both drugs produce weight loss as an effect. But the clinical comparison is not straightforward. Ozempic's weight-loss performance at its diabetes doses (0.5 mg to 1.0 mg weekly) is approximately 5-7%, because those doses were designed and tested for blood sugar control, not maximum fat loss. When semaglutide is used at the obesity dose of 2.4 mg weekly (Wegovy brand), the STEP 1 trial showed 14.9% mean body weight loss. Same molecule, different doses, different approved conditions.
For a deeper look at the molecular science without the brand-level complexity, see the tirzepatide vs semaglutide comparison. For those specifically comparing weight-loss brands, Wegovy vs Zepbound is the more direct pairing.
Side-by-Side Comparison
| Feature | Zepbound (tirzepatide) | Ozempic (semaglutide) |
|---|---|---|
| Molecule | Tirzepatide | Semaglutide |
| Developer | Eli Lilly | Novo Nordisk |
| Mechanism | Dual agonist (GLP-1 + GIP) | GLP-1 agonist (single) |
| FDA Indication | Chronic weight management | Type 2 diabetes |
| FDA Approval | November 2023 | 2017 (updated 2024) |
| Max Dose | 15 mg weekly | 1.0 mg (standard); 2.0 mg (extended, 2024) |
| Trial Weight Loss | 20.9% at 72 wks (SURMOUNT-1, obesity indication) | ~5-7% at T2D doses* |
| Half-Life | ~5 days | ~7 days |
| CV Outcome Data | Pending (SURPASS-CVOT ongoing) | Yes (SELECT 2023, 20% MACE reduction) |
*Wegovy (same semaglutide molecule at 2.4 mg) produced 14.9% weight loss in the STEP 1 obesity trial. Ozempic's diabetes doses were not designed or tested for maximum weight loss.
How They Work: Dual Agonist vs Single Agonist
The core biology separates these two drugs. Semaglutide (Ozempic) targets one receptor: the GLP-1 receptor. GLP-1 is a gut hormone that slows gastric emptying, activates satiety signals in the brain, and stimulates insulin release in response to elevated blood glucose. This single-receptor approach is effective for blood sugar management and produces moderate weight loss as a side benefit at diabetes doses.
Tirzepatide (Zepbound) hits two receptors simultaneously: GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). The GLP-1 component works identically to semaglutide. The GIP component adds a second layer: enhanced insulin secretion, improved insulin sensitivity, and direct effects on fat tissue metabolism. The combination of both signals appears to produce substantially greater average weight loss than GLP-1 alone.
Why the GIP Receptor Matters for Weight Loss
GIP receptors are expressed in fat tissue, and their activation appears to promote fat mobilization and energy expenditure beyond what GLP-1 alone achieves. The strongest clinical evidence comes from SURPASS-2, the only published head-to-head trial comparing tirzepatide directly to semaglutide. In a type 2 diabetes population of 1,879 people over 40 weeks, tirzepatide 15 mg produced 5.5 kg more body weight loss than semaglutide 1.0 mg (the T2D dose used in that trial).
Important SURPASS-2 Caveat
SURPASS-2 compared tirzepatide to semaglutide 1.0 mg (the approved diabetes dose, not the 2.4 mg weight-loss dose used in Wegovy trials). The 5.5 kg advantage for tirzepatide likely understates how the two molecules would compare in an obesity-indication, equal-dose head-to-head. No such trial has been completed as of 2026. (Frias et al., NEJM 2021)
FDA Approval and Indication: Why This Matters for Prescribing
The FDA indication determines how a drug is prescribed, what criteria you need to meet, and what insurance will typically cover. Mixing up the indications leads to coverage denials and off-label prescribing situations that most people don't anticipate.
Zepbound Prescribing Criteria
- BMI 30 or higher (obesity), OR
- BMI 27 or higher with at least one weight-related comorbidity (e.g., high blood pressure, sleep apnea, type 2 diabetes)
- FDA-approved for chronic weight management and, as of 2024, obstructive sleep apnea
- Approved: November 2023
Ozempic Prescribing Criteria
- Diagnosed type 2 diabetes
- Used as adjunct to diet and exercise for glycemic control
- Also indicated to reduce cardiovascular risk in adults with T2D and established CV disease
- Approved: 2017 (original); 2.0 mg dose extended in 2024
Can a Doctor Prescribe Ozempic for Weight Loss?
Yes, legally. Off-label prescribing is permitted in the United States and is routine in medical practice. But insurance coverage for Ozempic used off-label for weight loss is uncommon. Most commercial plans and Medicare Part D cover Ozempic for type 2 diabetes and typically deny coverage when the primary diagnosis code is obesity. Wegovy, semaglutide's on-label weight-loss brand, is the right product when weight management is the primary goal. Zepbound is the on-label choice when tirzepatide is the preferred molecule for weight loss.
Who Qualifies for Zepbound vs Ozempic?
Your doctor evaluates the following criteria based on your full health history.
For Zepbound, your doctor considers whether your BMI meets the obesity or overweight-with-comorbidity threshold and whether you have tried dietary and behavioral interventions. For Ozempic, the primary consideration is a confirmed type 2 diabetes diagnosis. If you have both type 2 diabetes and obesity, your doctor weighs which condition to treat first and what your insurance covers.
Weight Loss Results: What the Trials Show
Read the trial context before comparing numbers
Comparing Ozempic's weight-loss results to Zepbound's is like comparing Mounjaro's diabetes trial results to Wegovy's. The doses, populations, and study designs differ. Numbers that appear side by side in a table may not be measuring the same thing.
SURMOUNT-1: Zepbound's Obesity Trial
SURMOUNT-1 was a dedicated obesity-indication trial. Participants had BMI 30 or higher (or 27 with a comorbidity) and did not have type 2 diabetes. At 72 weeks on the 15 mg maximum dose, tirzepatide produced 20.9% mean body weight loss. 57% of participants at the 15 mg dose lost 20% or more of their body weight, an outcome previously seen only with bariatric surgery. (Jastreboff et al., NEJM, July 2022)
The Important Caveat on Ozempic Weight-Loss Numbers
When you see "semaglutide produces 14.9% weight loss," that figure comes from the STEP 1 trial using Wegovy at 2.4 mg in an obesity-indication population over 68 weeks. Ozempic's diabetes trials at 1.0 mg showed approximately 5-7% weight reduction as a secondary outcome. These are the same semaglutide molecule, but different doses for different approved purposes. Using the 14.9% number as Ozempic's weight-loss result is a common and misleading error. (Wilding et al., NEJM, March 2021)
SURPASS-2: The Only Head-to-Head Trial
SURPASS-2 enrolled 1,879 adults with type 2 diabetes inadequately controlled on metformin over 40 weeks. Tirzepatide 15 mg produced 5.5 kg more weight loss than the semaglutide 1.0 mg comparator arm. For HbA1c, tirzepatide 15 mg reduced levels by 2.30 percentage points versus 1.86 for semaglutide 1.0 mg. This trial ran in a type 2 diabetes population, and the semaglutide comparator was the 1.0 mg diabetes dose, not 2.4 mg. A head-to-head trial in an obesity-indication population with equal-dose comparison does not exist as of 2026. (Frias et al., NEJM 2021)
Weight Loss Summary
- Zepbound 15 mg (SURMOUNT-1, obesity, 72 wks): 20.9% mean body weight loss
- Wegovy 2.4 mg (STEP 1, obesity, 68 wks): 14.9% mean body weight loss
- Ozempic 1.0 mg (T2D trials, secondary outcome): ~5-7% weight reduction
- SURPASS-2 head-to-head (T2D population): tirzepatide 15 mg beat sema 1 mg by 5.5 kg
Dosing Comparison: Zepbound vs Ozempic
Both medications are administered as once-weekly subcutaneous injections. Both use prefilled autoinjector pens. Titration protocols differ in the number of dose steps and the endpoint dose.
Zepbound (Tirzepatide) Titration
| Step | Dose |
|---|---|
| Start | 2.5 mg |
| 4 wks | 5 mg |
| 8 wks | 7.5 mg |
| 12 wks | 10 mg |
| 16 wks | 12.5 mg |
| 20 wks | 15 mg |
Ozempic (Semaglutide) Titration
| Step | Dose |
|---|---|
| Start | 0.25 mg |
| 4 wks | 0.5 mg |
| 8 wks+ | 1.0 mg (standard max) |
| 2.0 mg extended dose approved 2024 for additional glycemic control | |
Titration Pace and Flexibility
Zepbound has six dose steps compared to Ozempic's three standard steps, both titrating at 4-week intervals. More steps in the tirzepatide protocol means more granular side-effect management during escalation. You can pause titration at any maintenance dose if side effects need more time to settle. Use the Zepbound dosing calculator or semaglutide dosing calculator to visualize drug-level curves over time.
Side Effects Comparison
Both drugs produce a GI-dominant side effect profile that is dose-dependent and generally mild to moderate in severity. Side effects typically peak during dose escalation and improve after each new dose level stabilizes.
Zepbound (Tirzepatide)
- Nausea (most common)
- Diarrhea
- Constipation
- Vomiting
- Decreased appetite
- Injection site reactions
Ozempic (Semaglutide)
- Nausea (most common)
- Diarrhea
- Constipation
- Vomiting
- Decreased appetite
- Injection site reactions
The profiles are nearly identical because both drugs slow gastric emptying and activate the same GLP-1 pathway. Both are dose-dependent: higher doses produce higher rates of GI symptoms. SURMOUNT-1 data (Jastreboff et al., NEJM 2022) showed tirzepatide adverse events leading to discontinuation in a small share of participants, at a rate comparable to semaglutide in the STEP trials.
Serious Side Effects (Both Drugs)
Black Box Warning (Both Drugs)
Both tirzepatide and semaglutide carry a black box warning for thyroid C-cell tumors based on rodent studies. Do not use either drug if you have a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.
Additional serious adverse events to discuss with your doctor:
- Pancreatitis (seek immediate care for severe, persistent abdominal pain)
- Gallbladder disease (cholelithiasis, cholecystitis)
- Hypoglycemia risk when combined with insulin or sulfonylureas (particularly relevant for Ozempic in T2D management)
- Acute kidney injury (from dehydration secondary to GI side effects)
Cardiovascular Outcomes: Ozempic's Key Advantage
If you have established cardiovascular disease, this section may be the most clinically relevant part of this comparison. Ozempic (semaglutide) has a large, completed cardiovascular outcomes trial. Zepbound (tirzepatide) does not yet, as of 2026.
SELECT Trial (2023): Semaglutide's Cardiovascular Landmark
The SELECT trial enrolled over 17,000 adults with obesity and established cardiovascular disease (but without diabetes) and randomized them to weekly semaglutide 2.4 mg or placebo. Results showed a 20% reduction in major adverse cardiovascular events (MACE): non-fatal heart attack, non-fatal stroke, or cardiovascular death, compared to placebo. (Lincoff et al., NEJM 2023)
This makes semaglutide the first and currently only obesity medication to demonstrate a cardiovascular mortality benefit in a dedicated outcomes trial.
Tirzepatide's cardiovascular outcomes trial (SURPASS-CVOT) is ongoing. Early data from type 2 diabetes trials show favorable trends, but no completed large-scale CV outcomes trial exists for tirzepatide in the obesity population as of early 2026. If you have both obesity and established cardiovascular disease, the semaglutide brand Wegovy (not Ozempic, which is approved for T2D) now carries a cardiovascular risk reduction indication. This distinction is worth discussing with your doctor.
Cost and Insurance Coverage
Both Zepbound and Ozempic are brand-name medications with list prices in the $900-$1,100 per month range without insurance at standard doses. Coverage decisions follow the FDA indication: insurance typically covers Ozempic when the diagnosis is type 2 diabetes, and Zepbound when the diagnosis is obesity meeting BMI criteria.
If you're prescribed Ozempic off-label for weight loss, insurance will generally deny coverage because the primary diagnosis code (obesity) doesn't match the approved indication (type 2 diabetes). The same logic applies in reverse: if you have obesity and no diabetes and request Ozempic instead of Zepbound for weight loss, your doctor faces a coverage and indication mismatch.
Compounded formulations of both tirzepatide and semaglutide have been available at significantly lower cost through certain compounding pharmacies, though regulatory status and availability vary. For more on tirzepatide pricing and compounding options, see Tirzepatide Hub.
Pricing Note
List prices change frequently. The $900-$1,100 range reflects typical 2024-2025 values for these drugs at standard doses. Always verify current pricing directly with the manufacturer savings programs (Lilly Cares for Zepbound, Novo Nordisk Patient Assistance for Ozempic) or your pharmacy.
Which Should You Choose? A Decision Framework
The following decision points are not medical recommendations. They describe the clinical and regulatory logic that guides prescribing. Your doctor evaluates your full health history.
If your primary diagnosis is type 2 diabetes
Ozempic is the on-label semaglutide choice for glycemic control. Mounjaro (tirzepatide's diabetes brand) is the on-label tirzepatide choice. Zepbound and Wegovy are weight-management brands of the same molecules and are not the labeled diabetes treatments.
If your primary goal is weight loss and you qualify for obesity medication
Zepbound is the on-label tirzepatide choice. Wegovy is the on-label semaglutide choice. These are the two weight-loss-approved brands to compare. See Wegovy vs Zepbound for that more direct pairing.
If you have obesity and established cardiovascular disease
Discuss the SELECT cardiovascular data with your doctor. Wegovy now carries a CV risk reduction indication based on SELECT results. Zepbound's CV outcomes trial data is not yet available. This distinction matters for anyone with high cardiovascular risk.
If you are comparing weight-loss drugs head-to-head
Compare Zepbound to Wegovy, not Ozempic. They are the obesity-indication versions of their respective molecules. The tirzepatide vs semaglutide article covers the molecular comparison without brand-level confusion.
Plan Your GLP-1 Dosing Schedule
Use our free calculators to model dose curves and titration timelines for either medication.
Video: Tirzepatide vs Semaglutide Explained
Board-certified gastroenterologist and obesity medicine specialist Dr. Christopher McGowan compares tirzepatide and semaglutide for weight loss.
Frequently Asked Questions
Is Zepbound better than Ozempic for weight loss?
In obesity trials, Zepbound (tirzepatide 15 mg) produced 20.9% mean body weight loss at 72 weeks. Ozempic is approved for type 2 diabetes, not weight loss, making a direct comparison imprecise. Ozempic's weight-loss equivalent, Wegovy (same semaglutide at 2.4 mg), produced 14.9% in the STEP 1 trial. A head-to-head obesity-indication trial between tirzepatide and semaglutide at equivalent doses has not been completed.
Can you switch from Ozempic to Zepbound?
Switching is possible under your doctor's guidance, but the indication changes from type 2 diabetes to weight management. The transition requires confirming eligibility for the obesity indication and adjusting the dose from scratch. Both drugs have different half-lives (~7 days for semaglutide, ~5 days for tirzepatide) that your doctor accounts for during the switch. Talk to your doctor before changing GLP-1 medications.
What is the biggest difference between Zepbound and Ozempic?
The biggest difference is FDA indication: Zepbound is approved for chronic weight management; Ozempic is approved for type 2 diabetes. Their molecules also differ: Zepbound contains tirzepatide (dual GLP-1 and GIP agonist) and Ozempic contains semaglutide (GLP-1 agonist only). This mechanism difference contributes to tirzepatide's generally greater weight-loss outcomes in clinical trials compared to semaglutide at equivalent dose levels.
Why would a doctor prescribe Zepbound instead of Ozempic?
Zepbound would be prescribed for obesity or weight management (BMI 30 or higher, or BMI 27 with a weight-related comorbidity) when type 2 diabetes is not the primary diagnosis. Ozempic is prescribed for type 2 diabetes. If you have both conditions, your doctor weighs which indication to prioritize, what insurance covers, and whether the dual-agonist mechanism of tirzepatide provides additional benefits.
Is Ozempic or Zepbound safer?
Both have similar GI side effect profiles (nausea, diarrhea, and vomiting are the most common) and both carry the same black box warning for thyroid C-cell tumors. Neither can be called categorically safer. The right choice depends on your individual health profile, existing conditions, and medication history. Ozempic has more long-term cardiovascular outcomes data from SELECT and diabetes trials.
Does Ozempic cause the same side effects as Zepbound?
Yes, largely. Both produce nausea, diarrhea, constipation, and vomiting as the most common side effects, and both are dose-dependent and mostly mild to moderate. Both carry the same thyroid tumor black box warning from the FDA label. GI side effects typically peak during the first few weeks after each dose increase and improve as the body adjusts to the new level.
How does Zepbound compare to Ozempic for type 2 diabetes?
Zepbound is not FDA-approved for type 2 diabetes. That is Mounjaro's role (same tirzepatide molecule). For diabetes, the relevant comparison is Mounjaro vs Ozempic, covered in the SURPASS-2 head-to-head trial. Mounjaro 15 mg reduced HbA1c by 2.30 percentage points versus 1.86 for Ozempic 1 mg over 40 weeks in 1,879 adults with type 2 diabetes (Frias et al., NEJM 2021).
Is Zepbound or Ozempic covered by insurance?
Insurance coverage follows the FDA indication. Ozempic is typically covered for type 2 diabetes. Zepbound is typically covered for obesity (BMI 30 or higher, or BMI 27 with comorbidity). Using either drug off-label, such as Ozempic for weight loss, usually results in coverage denial. Coverage varies widely by plan, and prior authorization is common for both drugs in most commercial insurance settings.
Can I take Ozempic and Zepbound together?
No. Combining two GLP-1 receptor agonists is contraindicated. Both drugs work through overlapping receptor pathways and combining them provides no additional clinical benefit while substantially increasing adverse effect risk. Using both simultaneously is not clinically recommended or FDA-approved for any indication. This applies to all GLP-1 medication combinations.
What is the cost difference between Zepbound and Ozempic?
Both have list prices in a similar range without insurance (approximately $900-$1,100 per month at standard doses). With insurance, coverage depends on diagnosis: Ozempic is often covered for type 2 diabetes; Zepbound for qualifying obesity. Both are available as compounded formulations at significantly lower cost through certain providers. Manufacturer savings programs (Lilly Cares, Novo Nordisk assistance) may reduce out-of-pocket costs for those who qualify.
References
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216. doi:10.1056/NEJMoa2206038.
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183.
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. 2023;389(24):2221-2232. doi:10.1056/NEJMoa2307563.
- Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). N Engl J Med. 2021;385(6):503-515. doi:10.1056/NEJMoa2107519.
- FDA. Zepbound (tirzepatide) Prescribing Information. NDA 217806. Eli Lilly and Company. 2023.
- FDA. Ozempic (semaglutide) Prescribing Information. NDA 209637. Novo Nordisk. 2017 (updated 2024).
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. The comparison of Zepbound and Ozempic reflects clinical trial data and FDA labeling as of April 2026. Always consult a qualified healthcare provider before starting, changing, or stopping any medication. Individual results vary. Neither tirzepatide nor semaglutide should be used without medical supervision and a valid prescription from a licensed clinician.
Track Your GLP-1 Schedule
GLP3Planner is a free pharmacokinetic calculator for tirzepatide, semaglutide, and retatrutide. Model drug levels, plan titration, and track your doses.
Related Articles
Tirzepatide vs Semaglutide
The molecular comparison without brand complexity. Mechanism, pharmacokinetics, and trial outcomes side by side.
Ozempic vs Wegovy
Same semaglutide molecule, different doses and indications. Explains the semaglutide brand split in full.
Mounjaro vs Zepbound
Same tirzepatide molecule, different indications. The diabetes vs weight-loss brand split explained.
Tirzepatide Weight Loss Guide
Deep-dive on Zepbound outcomes: SURMOUNT-1 data, what 20.9% weight loss means, and realistic expectations.
Zepbound Side Effects
What to expect on Zepbound: nausea timelines, management strategies, and when to call your doctor.